BeiGene Reports Record $1.4 Billion Quarterly Revenue as BRUKINSA Surpasses $1 Billion Milestone
Key Insights
BeiGene (search) achieved record third-quarter 2025 revenue of $1.4 billion, representing 41% year-over-year growth, driven by BRUKINSA becoming the first product to exceed $1 billion in quarterly sales.
The company reported positive GAAP earnings of $1.09 per ADS and generated $354 million in free cash flow, prompting management to raise full-year 2025 revenue guidance to $5.1-5.3 billion.
BeiGene (search)'s pipeline advances include sonrotoclax receiving FDA Breakthrough Therapy designation for mantle cell lymphoma (search), with pivotal data expected by end of 2026.
BeiGene (search) delivered exceptional third-quarter 2025 financial results, with revenue surging 41% year-over-year to reach $1.4 billion, driven primarily by its flagship BTK (search) inhibitor BRUKINSA surpassing $1 billion in quarterly sales for the first time. The oncology-focused biotechnology company reported GAAP earnings per ADS of $1.09, marking an improvement of over $2 compared to the same period last year.
Strong Financial Performance Drives Guidance Raise
The quarter generated $354 million in free cash flow, boosting total cash and equivalents to $4.1 billion. Based on this robust performance, management raised its full-year 2025 revenue guidance to a range of $5.1 billion to $5.3 billion. BeiGene (search) now anticipates achieving positive GAAP operating income and positive free cash flow for the entirety of 2025.
Market analysts have responded positively to the company's trajectory, with consensus price targets standing at $397.66, suggesting approximately 21.8% upside potential from recent trading levels near $321. Individual forecasts range from $362 to $424, with RBC Capital Markets (search) recently increasing its target from $395 to $408.
Pipeline Advances Toward Key Regulatory Milestones
Beyond commercial success, BeiGene (search) is progressing a diverse clinical pipeline with several assets approaching major milestones. Sonrotoclax, a BCL2 (search) inhibitor, has secured both Breakthrough Therapy designation and Priority Review from the U.S. FDA (search) for its application in mantle cell lymphoma (search). Pivotal trial data and global regulatory submissions are anticipated by the end of 2026.
The company's BTK (search) degrader (BGB-16673) is currently in a Phase 3 trial directly comparing it to ibrutinib, with critical Phase 2 data in chronic lymphocytic leukemia (search) expected in the first half of 2026.
Solid Tumor Portfolio Shows Promise
BeiGene (search)'s solid tumor portfolio, which includes a CDK4 (search) inhibitor and a B7-H4 (search) antibody-drug conjugate, has demonstrated proof of concept. Phase 3 studies in first-line breast cancer (search) and pancreatic cancer (search) are scheduled to begin in 2026. The company plans to introduce more than 10 novel drug candidates into clinical development before the close of 2026.
This combination of financial strength and a clearly articulated development roadmap positions BeiGene (search) for continued growth, with shares demonstrating resilience and trading activity showing typical biotech sector volatility around the $320 mark while maintaining strong underlying fundamentals.